Cladribine (French Wikipedia)

Analysis of information sources in references of the Wikipedia article "Cladribine" in French language version.

refsWebsite

Global rank French rank

21nih.gov

4^th place

12^th place

21doi.org

2^nd place

3^rd place

8semanticscholar.org

11^th place

325^th place

5europa.eu

68^th place

67^th place

4web.archive.org

1^st place

3elsevier.com

610^th place

265^th place

2sagepub.com

731^st place

771^st place

1drugs.com

399^th place

2,761^st place

1tga.gov.au

3,984^th place

low place

1medicines.org.uk

3,823^rd place

low place

1histio.org

low place

1nasonline.org

3,325^th place

6,274^th place

1pharmamedtechbi.com

low place

1scripps.edu

low place

1mult-sclerosis.org

low place

1wsj.com

79^th place

267^th place

1nytimes.com

7^th place

28^th place

1tevapharm.com

low place

1firstwordpharma.com

low place

1medpagetoday.com

9,274^th place

low place

1fiercebiotech.com

low place

1merckgroup.com

low place

1lww.com

2,769^th place

931^st place

1nejm.org

2,374^th place

298^th place

1springer.com

274^th place

223^rd place

1ectrims-congress.eu

low place

1msard-journal.com

low place

doi.org

dx.doi.org

Liliemark J, « The clinical pharmacokinetics of cladribine », Clinical Pharmacokinetics, vol. 32, n^o 2,‎ février 1997, p. 120–31 (PMID 9068927, DOI 10.2165/00003088-199732020-00003, S2CID 32926069)
Giovannoni, « Cladribine to Treat Relapsing Forms of Multiple Sclerosis », Neurotherapeutics, vol. 14, n^o 4,‎ 2017, p. 874–887 (PMID 29168160, PMCID 5722776, DOI 10.1007/s13311-017-0573-4)
Leist et Weissert, « Cladribine », Clinical Neuropharmacology, vol. 34, n^o 1,‎ 2011, p. 28–35 (PMID 21242742, DOI 10.1097/WNF.0b013e318204cd90, S2CID 43201228, lire en ligne)
« Langerhans cell histiocytosis in children: from the bench to bedside for an updated therapy », British Journal of Haematology, vol. 173, n^o 5,‎ juin 2016, p. 663–70 (PMID 26913480, DOI 10.1111/bjh.13955) :
« The combination of cytarabine and cladribine is the current standard for second-line therapy of refractory cases with vital organ dysfunction. »
Rammohan, « The Development of Cladribine Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review », Drugs, vol. 80, n^o 18,‎ 2020, p. 1901–1928 (PMID 33247831, PMCID 7708385, DOI 10.1007/s40265-020-01422-9)
Johnston, « Mechanism of Action of Pentostatin and Cladribine in Hairy Cell Leukemia », Leukemia & Lymphoma, vol. 52,‎ 2011, p. 43–45 (PMID 21463108, DOI 10.3109/10428194.2011.570394, S2CID 207508023, lire en ligne)
« 2-Chlorodeoxyadenosine (2-CdA): A Potent Chemotherapeutic and Immunosuppressive Nucleoside », Leukemia & Lymphoma, vol. 5, n^o 1,‎ 1991, p. 1–8 (PMID 27463204, DOI 10.3109/10428199109068099)
« Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells », Journal of Neurology, vol. 265, n^o 5,‎ mai 2018, p. 1199–1209 (PMID 29550884, PMCID 5937883, DOI 10.1007/s00415-018-8830-y)
« Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis », EBioMedicine, vol. 16,‎ février 2017, p. 41–50 (PMID 28161400, PMCID 5474520, DOI 10.1016/j.ebiom.2017.01.042)
« Both cladribine and alemtuzumab may effect MS via B-cell depletion », Neurology, vol. 4, n^o 4,‎ juillet 2017, e360 (PMID 28626781, PMCID 5459792, DOI 10.1212/NXI.0000000000000360)
« No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine », Neurology, vol. 2, n^o 6,‎ décembre 2015, e158 (PMID 26468472, PMCID 4592538, DOI 10.1212/nxi.0000000000000158)
Giovannoni, « Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study », Mult Scler, vol. 24, n^o 12,‎ 2018, p. 1594–1604 (PMID 28870107, DOI 10.1177/1352458517727603, S2CID 1910070, lire en ligne)
Giovannoni, « A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis », N Engl J Med, vol. 362, n^o 5,‎ 2010, p. 416–26 (PMID 20089960, DOI 10.1056/NEJMoa0902533, lire en ligne)
Giovannoni, « Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis », Lancet Neurol, vol. 10, n^o 4,‎ 2011, p. 329–337 (PMID 21397565, DOI 10.1016/S1474-4422(11)70023-0, S2CID 20149620, lire en ligne)
Comi, « MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study », J Neurol, vol. 260, n^o 4,‎ 2013, p. 1136–46 (PMID 23263473, DOI 10.1007/s00415-012-6775-0, S2CID 8934723, lire en ligne)
Comi, « Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis », Mult Scler Relat Disord, vol. 29,‎ 2019, p. 168–74 (PMID 30885375, DOI 10.1016/j.msard.2019.01.038, S2CID 83461539, lire en ligne)
Giovannoni, « Efficacy of cladribine tTablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study », Mult Scler, vol. 25, n^o 6,‎ 2019, p. 819–27 (PMID 29716436, PMCID 6460686, DOI 10.1177/1352458518771875)
Rammohan, « Cladribine tablets for relapsing-remitting multiple sclerosis: Efficacy across patient subgroups from the phase III CLARITY study », Mult Scler Relat Disord, vol. 1, n^o 1,‎ 2012, p. 49–54 (PMID 25876451, DOI 10.1016/j.msard.2011.08.006, lire en ligne)
Cook, « Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis », Mult Scler Relat Disord, vol. 29,‎ 2019, p. 157–67 (PMID 30885374, DOI 10.1016/j.msard.2018.11.021, S2CID 81873347, lire en ligne)
« Epigenetic therapy overcomes treatment resistance in T cell prolymphocytic leukaemia », Science Translational Medicine, vol. 7, n^o 293,‎ juin 2015, p. 293ra102 (PMID 26109102, PMCID 4807901, DOI 10.1126/scitranslmed.aaa5079)

doi.org

Johnston, « Mechanism of Action of Pentostatin and Cladribine in Hairy Cell Leukemia », Leukemia & Lymphoma, vol. 52,‎ 2011, p. 43–45 (PMID 21463108, DOI 10.3109/10428194.2011.570394, S2CID 207508023, lire en ligne)

drugs.com

« Cladribine », sur Drugs.com, 28 février 2020 (consulté le 4 mars 2020)

ectrims-congress.eu

onlinelibrary.ectrims-congress.eu

Giovannoni, « An exploratory analysis of the efficacy of cladribine tablets 3.5mg/kg in patients with relapsing multiple sclerosis stratified according to age above and below 45 years in the CLARITY study », Ectrims,‎ 2018, P1204 (lire en ligne)

elsevier.com

linkinghub.elsevier.com

Giovannoni, « Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis », Lancet Neurol, vol. 10, n^o 4,‎ 2011, p. 329–337 (PMID 21397565, DOI 10.1016/S1474-4422(11)70023-0, S2CID 20149620, lire en ligne)
Comi, « Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis », Mult Scler Relat Disord, vol. 29,‎ 2019, p. 168–74 (PMID 30885375, DOI 10.1016/j.msard.2019.01.038, S2CID 83461539, lire en ligne)
Rammohan, « Cladribine tablets for relapsing-remitting multiple sclerosis: Efficacy across patient subgroups from the phase III CLARITY study », Mult Scler Relat Disord, vol. 1, n^o 1,‎ 2012, p. 49–54 (PMID 25876451, DOI 10.1016/j.msard.2011.08.006, lire en ligne)

europa.eu

ema.europa.eu

« European Medicines Agency - - Litak », European Medicines Agency - - Litak,‎ 3 juin 2006 (lire en ligne)
« Mavenclad EU SmPC, February 2021 », European Medicines Agency, February 2021
« Litak EMA package: Scientific Discussion », Europeans Medicines Agency, 2004
« Litak: Background Information on the Procedure », Europeans Medicines Agency, 2004
« Withdrawal Assessment Report for Movectro », Europeans Medicines Agency, 2011 : « Procedure No. EMEA/H/C/001197 »

fiercebiotech.com

« Four years after a transatlantic slapdown, Merck KGaA will once again seek cladribine OK », Fierce Biotech

firstwordpharma.com

Staff, « Merck KGaA to acquire Serono », First Word Pharma, 21 septembre 2006

histio.org

« Erdheim-Chester Disease » [archive du 6 juin 2019], Histiocytosis Association

lww.com

journals.lww.com

Giovannoni G. Curr Opin Neurol 2018;31(3):233–43 doi : 10.1097/WCO.0000000000000561

medicines.org.uk

« Leustat Injection. EMC, Summary of Product Characteristics (SPC) », Leustat Injection. - Summary of Product Characteristics (SPC),‎ 19 janvier 2022 (lire en ligne [archive du 3 octobre 2017], consulté le 19 août 2016)

medpagetoday.com

« Merck KGaA Throws in Towel on Cladribine for MS », 22 juin 2011

merckgroup.com

« Cladribine approved in Europe », Merck Press Release, 25 août 2017

msard-journal.com

Cook, « Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis », Mult Scler Relat Disord, vol. 29,‎ 2019, p. 157–67 (PMID 30885374, DOI 10.1016/j.msard.2018.11.021, S2CID 81873347, lire en ligne)

mult-sclerosis.org

« Ivax to Develop Cladribine for Multiple Sclerosis », 4 décembre 2000

nasonline.org

« Biographical Memoir: Ernest Beutler 1928–2008 », National Academy of Sciences, 2012

nejm.org

Giovannoni, « A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis », N Engl J Med, vol. 362, n^o 5,‎ 2010, p. 416–26 (PMID 20089960, DOI 10.1056/NEJMoa0902533, lire en ligne)

nih.gov

ncbi.nlm.nih.gov

Liliemark J, « The clinical pharmacokinetics of cladribine », Clinical Pharmacokinetics, vol. 32, n^o 2,‎ février 1997, p. 120–31 (PMID 9068927, DOI 10.2165/00003088-199732020-00003, S2CID 32926069)
Giovannoni, « Cladribine to Treat Relapsing Forms of Multiple Sclerosis », Neurotherapeutics, vol. 14, n^o 4,‎ 2017, p. 874–887 (PMID 29168160, PMCID 5722776, DOI 10.1007/s13311-017-0573-4)
Leist et Weissert, « Cladribine », Clinical Neuropharmacology, vol. 34, n^o 1,‎ 2011, p. 28–35 (PMID 21242742, DOI 10.1097/WNF.0b013e318204cd90, S2CID 43201228, lire en ligne)
« Langerhans cell histiocytosis in children: from the bench to bedside for an updated therapy », British Journal of Haematology, vol. 173, n^o 5,‎ juin 2016, p. 663–70 (PMID 26913480, DOI 10.1111/bjh.13955) :
« The combination of cytarabine and cladribine is the current standard for second-line therapy of refractory cases with vital organ dysfunction. »
Rammohan, « The Development of Cladribine Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review », Drugs, vol. 80, n^o 18,‎ 2020, p. 1901–1928 (PMID 33247831, PMCID 7708385, DOI 10.1007/s40265-020-01422-9)
Johnston, « Mechanism of Action of Pentostatin and Cladribine in Hairy Cell Leukemia », Leukemia & Lymphoma, vol. 52,‎ 2011, p. 43–45 (PMID 21463108, DOI 10.3109/10428194.2011.570394, S2CID 207508023, lire en ligne)
« 2-Chlorodeoxyadenosine (2-CdA): A Potent Chemotherapeutic and Immunosuppressive Nucleoside », Leukemia & Lymphoma, vol. 5, n^o 1,‎ 1991, p. 1–8 (PMID 27463204, DOI 10.3109/10428199109068099)
« Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells », Journal of Neurology, vol. 265, n^o 5,‎ mai 2018, p. 1199–1209 (PMID 29550884, PMCID 5937883, DOI 10.1007/s00415-018-8830-y)
« Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis », EBioMedicine, vol. 16,‎ février 2017, p. 41–50 (PMID 28161400, PMCID 5474520, DOI 10.1016/j.ebiom.2017.01.042)
« Both cladribine and alemtuzumab may effect MS via B-cell depletion », Neurology, vol. 4, n^o 4,‎ juillet 2017, e360 (PMID 28626781, PMCID 5459792, DOI 10.1212/NXI.0000000000000360)
« No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine », Neurology, vol. 2, n^o 6,‎ décembre 2015, e158 (PMID 26468472, PMCID 4592538, DOI 10.1212/nxi.0000000000000158)
Giovannoni, « Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study », Mult Scler, vol. 24, n^o 12,‎ 2018, p. 1594–1604 (PMID 28870107, DOI 10.1177/1352458517727603, S2CID 1910070, lire en ligne)
Giovannoni, « A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis », N Engl J Med, vol. 362, n^o 5,‎ 2010, p. 416–26 (PMID 20089960, DOI 10.1056/NEJMoa0902533, lire en ligne)
Giovannoni, « Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis », Lancet Neurol, vol. 10, n^o 4,‎ 2011, p. 329–337 (PMID 21397565, DOI 10.1016/S1474-4422(11)70023-0, S2CID 20149620, lire en ligne)
Comi, « MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study », J Neurol, vol. 260, n^o 4,‎ 2013, p. 1136–46 (PMID 23263473, DOI 10.1007/s00415-012-6775-0, S2CID 8934723, lire en ligne)
Comi, « Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis », Mult Scler Relat Disord, vol. 29,‎ 2019, p. 168–74 (PMID 30885375, DOI 10.1016/j.msard.2019.01.038, S2CID 83461539, lire en ligne)
Giovannoni, « Efficacy of cladribine tTablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study », Mult Scler, vol. 25, n^o 6,‎ 2019, p. 819–27 (PMID 29716436, PMCID 6460686, DOI 10.1177/1352458518771875)
Rammohan, « Cladribine tablets for relapsing-remitting multiple sclerosis: Efficacy across patient subgroups from the phase III CLARITY study », Mult Scler Relat Disord, vol. 1, n^o 1,‎ 2012, p. 49–54 (PMID 25876451, DOI 10.1016/j.msard.2011.08.006, lire en ligne)
Cook, « Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis », Mult Scler Relat Disord, vol. 29,‎ 2019, p. 157–67 (PMID 30885374, DOI 10.1016/j.msard.2018.11.021, S2CID 81873347, lire en ligne)
« Epigenetic therapy overcomes treatment resistance in T cell prolymphocytic leukaemia », Science Translational Medicine, vol. 7, n^o 293,‎ juin 2015, p. 293ra102 (PMID 26109102, PMCID 4807901, DOI 10.1126/scitranslmed.aaa5079)

dailymed.nlm.nih.gov

« Cladribine- cladribine injection », DailyMed, 31 décembre 2019 (consulté le 4 mars 2020)

nytimes.com

« Teva to Acquire Ivax, Another Maker of Generic Drugs », New York Times, 26 juillet 2005

pharmamedtechbi.com

pink.pharmamedtechbi.com

Staff, « Ortho Biotech's Leustatin For Hairy Cell Leukemia », The Pink Sheet,‎ 8 mars 1993 (lire en ligne [archive du 3 octobre 2017])

sagepub.com

journals.sagepub.com

Soelberg Sorensen P, Sellebjerg F. Ther Adv Neurol Disord 2019;12:1756286419836913. doi: 10.1177/1756286419836913
Giovannoni, « Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study », Mult Scler, vol. 24, n^o 12,‎ 2018, p. 1594–1604 (PMID 28870107, DOI 10.1177/1352458517727603, S2CID 1910070, lire en ligne)

scripps.edu

Sauter et Ono, « A potential new MS treatment's long and winding road », News & Views - Scripps Research Institute

semanticscholar.org

api.semanticscholar.org

Liliemark J, « The clinical pharmacokinetics of cladribine », Clinical Pharmacokinetics, vol. 32, n^o 2,‎ février 1997, p. 120–31 (PMID 9068927, DOI 10.2165/00003088-199732020-00003, S2CID 32926069)
Leist et Weissert, « Cladribine », Clinical Neuropharmacology, vol. 34, n^o 1,‎ 2011, p. 28–35 (PMID 21242742, DOI 10.1097/WNF.0b013e318204cd90, S2CID 43201228, lire en ligne)
Johnston, « Mechanism of Action of Pentostatin and Cladribine in Hairy Cell Leukemia », Leukemia & Lymphoma, vol. 52,‎ 2011, p. 43–45 (PMID 21463108, DOI 10.3109/10428194.2011.570394, S2CID 207508023, lire en ligne)
Giovannoni, « Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study », Mult Scler, vol. 24, n^o 12,‎ 2018, p. 1594–1604 (PMID 28870107, DOI 10.1177/1352458517727603, S2CID 1910070, lire en ligne)
Giovannoni, « Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis », Lancet Neurol, vol. 10, n^o 4,‎ 2011, p. 329–337 (PMID 21397565, DOI 10.1016/S1474-4422(11)70023-0, S2CID 20149620, lire en ligne)
Comi, « MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study », J Neurol, vol. 260, n^o 4,‎ 2013, p. 1136–46 (PMID 23263473, DOI 10.1007/s00415-012-6775-0, S2CID 8934723, lire en ligne)
Comi, « Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis », Mult Scler Relat Disord, vol. 29,‎ 2019, p. 168–74 (PMID 30885375, DOI 10.1016/j.msard.2019.01.038, S2CID 83461539, lire en ligne)
Cook, « Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis », Mult Scler Relat Disord, vol. 29,‎ 2019, p. 157–67 (PMID 30885374, DOI 10.1016/j.msard.2018.11.021, S2CID 81873347, lire en ligne)

springer.com

link.springer.com

Comi, « MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study », J Neurol, vol. 260, n^o 4,‎ 2013, p. 1136–46 (PMID 23263473, DOI 10.1007/s00415-012-6775-0, S2CID 8934723, lire en ligne)

tevapharm.com

« Teva Completes Acquisition of Ivax » [archive du 18 décembre 2019], Teva Press Release, 2006 (consulté le 21 août 2016)

tga.gov.au

ebs.tga.gov.au

« PRODUCT INFORMATION LITAK© 2 mg/mL solution for injection » [PDF], sur TGA eBusiness Services, St Leonards, Australia, Orphan Australia Pty. Ltd, 10 mai 2010 (consulté le 27 novembre 2014)

web.archive.org

« Leustat Injection. EMC, Summary of Product Characteristics (SPC) », Leustat Injection. - Summary of Product Characteristics (SPC),‎ 19 janvier 2022 (lire en ligne [archive du 3 octobre 2017], consulté le 19 août 2016)
« Erdheim-Chester Disease » [archive du 6 juin 2019], Histiocytosis Association
Staff, « Ortho Biotech's Leustatin For Hairy Cell Leukemia », The Pink Sheet,‎ 8 mars 1993 (lire en ligne [archive du 3 octobre 2017])
« Teva Completes Acquisition of Ivax » [archive du 18 décembre 2019], Teva Press Release, 2006 (consulté le 21 août 2016)

wsj.com

« Serono Purchases Rights To Experimental MS Drug », Dow Jones Newswires in the Wall Street Journal, 31 octobre 2002